Primary Spinal Neurocytoma Involving the Medulla Oblongata: Two Case Reports and a Literature Review

Liang Wu,1 Xiaofeng Deng,1 Chenlong Yang,1 Lei Zhao,1 Tao Yang,1 and Yulun Xu1

1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Abstract

Central neurocytoma is a rare neuroectodermal tumor found in young adults. These tumors are generally located in the lateral or third ventricles. Extraventricular neurocytoma in the spinal cord is extremely rare. We report on two patients with primary spinal neurocytomas who presented with progressive numbness and weakness in the limbs. Both patients had intramedullary masses between the medulla and the upper thoracic levels. The clinical, radiological, surgical, and pathological features of this abnormality are discussed, and all 20 reported cases were reviewed. In conclusion, neurocytoma should be included in the differential diagnosis of a spinal intramedullary tumor, and subtotal resection is acceptable for a relatively favorable prognosis if gross total removal is unachievable. The efficacy of adjuvant radiochemotherapy to control tumor recurrence is unknown.

Key words: neurocytoma, spinal cord, extraventricular, medulla oblongata, magnetic resonance imaging

Introduction

Central neurocytoma (CN) is a rare tumor that is typically located in the supratentorial ventricular system near the foramen of Monro. It was first described by Hassoun et al. in 1982 and accounts for only 0.1–0.5% of all primary intracranial tumors.1) Primary tumors with the morphological and histological features of CN have been described at extraventricular sites, including the cerebral parenchyma, thalamus, cerebellum and spinal cord.2,3) Spinal neurocytoma (Sn) is extremely rare, and Sns, which usually mimic common intraspinal tumors, are generally found in intramedullary locations. Therefore, it may be difficult to make a correct preoperative diagnosis. This report details the cases of two patients who were admitted to our department between 2008 and 2010 with intramedullary SNs located between the medulla and the upper thoracic levels. Their clinical data were retrospectively evaluated, and a review of all other known cases in the English literature was performed.

Case Report

I. Case 1

A 48-year-old female presented to our outpatient clinic with an 8-year history of intermittent pain in her right lower limb. She had developed progressive worsening numbness of both the upper and lower limbs for the previous 5 years. She reported experiencing no bowel or bladder symptoms. A neurological examination revealed that muscle tone was increased in the right lower limb, and the muscle power was grade 4/5 (classified by the Medical Research Council grading system). Deep and superficial sensations in her right leg and superficial sensation in her left arm were reduced. Her right lower limb also showed amyotrophy, increased deep tendon reflexes, and a positive Babinski sign.

Preoperative magnetic resonance imaging (MRI) of the patient’s cervical spine demonstrated an intramedullary lesion in the medulla to T1 spinal segments (Fig. 1A–D). The tumor appeared to be composed of multiple irregular nodules that were iso-/hypointense on T1-weighted images and mixed hyperintense on T2-weighted images. A contrast-enhanced MRI of the lesion showed heterogeneous enhancement after gadolinium administration. Abnormal flow void signals and associated syringomyelia were not observed. According to the location and MRI features of the tumor, the differential diagnosis included ependymoma and astrocytoma.

The patient underwent a C1 to T2 laminectomy using a posterior approach. The dura was tense, and a longitudinal incision was made in its center. The spinal cord was
swollen and thickened. The intraoperative findings showed that the tumor had incomplete capsule and was red-grayish in color, soft, and moderately vascular. Because of the tumor’s adhesion to the spinal cord and its ill-defined margins with the medulla, en bloc resection would have been difficult to achieve. For this reason, the intramedullary tumor was subtotally removed under spinal evoked-potential monitoring based on the need to protect the patient’s spinal functions.

A histopathological examination revealed that the tumor was composed of areas of delicate fibrillary neuropils and sheets of uniform, small, round cells with finely speckled vesicular nuclei. Most cells showed clear perinuclear halos and appeared to form honeycomb structures that resembled those seen in oligodendrogliomas (Fig. 2A–C). Mitosis, necrosis, and vascular proliferation were absent. The immunohistochemical examinations revealed that the tumor cells were positive for synaptophysin (Syn), neuron-specific enolase (NSE), and S-100 but negative for glial fibrillary acidic protein, chromogranin, neurofilament, and epithelial membrane antigen. In particular, cytoplasmic positivity for Syn and nuclear positivity for NeuN was observed in the tumor cells (Fig. 3). All the findings were consistent with a diagnosis of extraventricular neurocytoma (eVN).

In the immediate postoperative period, the weakness in the patient’s right lower limb worsened (muscle power of grade 2/5) but improved to a satisfactory level within 6 months postoperatively. At the 18-month follow-up MRI examination, no tumor recurrence or regrowth was found.

II. Case 2

A 26-year-old male presented with progressive increasing numbness and weakness in his right upper and lower limbs over the previous 9 months. He had noticed weakness in his left upper limb for 5 months. The bilateral weakness spread slowly upward, beginning from the distal limbs. A neurological examination revealed that muscle power was Grade 4/5 in his right side and left upper limb. Sensations to pinpricks and light touch on

Fig. 1 Case 1. A preoperative magnetic resonance imaging (MRI) showing a medulla-T1 intramedullary mass with iso-/hypointensity on the sagittal T₁-weighted image (A), mixed hyperintensity on the sagittal T₂-weighted image (B), and heterogeneous enhancement on the sagittal (C) and axial (D) T₁-weighted images with gadolinium. Case 2. A preoperative MRI showing a medulla-T4 ill-defined intramedullary mass with iso-/hypo-intensity on the sagittal T₁-weighted image (E), hyperintensity on the sagittal T₁-weighted image (F), and heterogeneous enhancement at the C3–C7 levels and linear enhancement on the surface of the cerebellum, brainstem, and spinal cord on the sagittal (G) and axial (H) T₁-weighted images with gadolinium.
Primary Spinal Neurocytoma

Fig. 2 Photomicrographs of the surgical specimens in Case 1 (A–C) and Case 2 (D–F) illustrating sheets of uniform small round cells with finely speckled vesicular nuclei, clear perinuclear halos in areas of delicate fibrillary neuropils (A, D: hematoxylin–eosin stain, original magnification ×100; B, E: hematoxylin–eosin stain, original magnification ×200), and strong positivity for synaptophysin (C: original magnification ×100; F: original magnification ×200).

Fig. 3 Photomicrographs of the surgical specimens in Case 1 showing cytoplasmic positivity for synaptophysin (A) and nuclear positivity for NeuN (B) in the tumor cells (original magnification ×400).

the right foot were decreased, and joint position sense in the lower limbs was poor. Amyotrophy was noted in the right leg. A spinal examination was unremarkable, with no local tenderness or deformity.

A preoperative MRI of the cervical spine showed an ill-defined intramedullary lesion in the medulla to T4 spinal segments (Fig. 1E–H). The mass was iso-/hypointense on T₁-weighted images and hyperintense on T₂-weighted images. The T₁-weighted imaging with gadolinium showed heterogeneous enhancement at the C3–C7 levels and linear enhancement at the surface of the cerebellum, brainstem, and spinal cord. The preoperative differential diagnosis

Neurol Med Chir (Tokyo) 54, May, 2014
included ependymoma, astrocytoma, and metastasis. A total C3–C7 laminectomy using a high-speed drill revealed a dark grayish, soft, ill-defined, extremely vascular tumor. Because of adhesions to the spinal cord and the high degree of vascularity, the tumor was subtotally removed. A retention suture was performed using an artificial dural patch, and no vertebral lamina reduction was performed for decompression.

The histopathological findings showed the typical morphological features of CN: round tumor cells with perinuclear halos mimicking the appearance of oligodendroglioma cells. The diagnosis was confirmed by immunostaining (Fig. 2D–F).

The postoperative course was uneventful, and the patient's sensory deficits were apparently relieved. Because of the risk of tumor recurrence and metastasis, further treatment was strongly recommended. However, the patient refused to undergo adjuvant radiotherapy and chemotherapy. He left the hospital 2 weeks after surgery. Gradual improvement in limb strength was noted during the follow-up examinations. A 2-year postoperative MRI showed that the tumor had not recurred or metastasized.

**Discussion**

Since Coca et al. described the first case in 1994, only 18 cases of primary SN have been reported in the English literature. Table 1 summarizes the clinical features of previous cases and our two patients. Of the 20 reported patients, 14 were male and 6 were female. Compared with CNs and other EVNs, in which gender predominance is not evident, the male/female ratio of primary SNs (2.3:1) suggests a strong male predilection. The mean age at presentation is 33.7 years, which is similar to that of other EVNs. The tumors tend to arise from the cervical and thoracic spinal regions. Two cases involved the medulla oblongata, and two tumors were located in the lumbar segment. In the previous cases, all the lesions were intramedullary, including one with an extramedullary component.

The signs and symptoms of SNs are consistent with those of other common intramedullary spinal tumors. The clinical presentations of SNs include somatic pain, numbness, progressive or sudden weakness in the limbs, and incomplete voiding when the conus medullaris is involved. The symptoms usually evolve over a period of months to years. Regardless of the duration, rapid deterioration occurred in a few cases, most likely caused by venous thrombosis and tumor hemorrhage.

The MRI features of primary SNs are variable and could be misleading, as shown in the previously reported cases. All the cases involved intramedullary tumors; associated syringomyelia could be found, but this finding was uncommon. The signals of primary SNs ranged from iso- to hypointensity on T₁-weighted images and iso- to hyperintensity on T₂-weighted images. The lesions could show homo- or heterogeneous enhancement after gadolinium administration and some had poorly defined tumor margins. These features were similar to those of spinal cord ependymomas and astrocytomas. In our two cases, variations in the preoperative MRI findings led to difficulties with the diagnosis. Both lesions involved the medulla. Thus, a definitive diagnosis of primary SN was difficult based on MRI alone, and a complete histopathological examination was required to differentiate between other common intramedullary tumors, such as ependymomas, astrocytomas, and oligodendrogliomas in particular.

The histogenesis of CN is poorly understood, but some theories have been proposed. CN may originate from cells that are committed to a neuronal phenotype or from bipotential progenitor cells in the periventricular matrix. The differential diagnosis for SN typically includes other intramedullary tumors, particularly ependymoma and oligodendroglioma. Neurocytomas have a fine neuropil-like fibrillary matrix instead of the coarser glial fibrillary matrix of ependymomas. Cells of ependymomas exhibit more angulated nuclei and are negative for Syn. Neurocytoma cells show clear perinuclear halos that resemble oligodendroglialomas. Thus, immunohistochemistry is often a necessary adjunct for the differential diagnosis.

Strong and diffuse immunostaining for Syn has been recognized as the most suitable and reliable diagnostic marker. The nuclear positivity for NeuN favors diagnosing SN over oligodendroglioma, although the latter can also occasionally express neuronal markers. In the literature, SNs have reportedly expressed some other neuronal markers, including NSE, neuron-associated class III beta-tubulin, and microtubule-associated protein 2. However, chromogranin and neurofilament proteins are generally absent.

Because of the benign nature and well differentiation of this tumor, complete resection is advised to ensure a relatively favorable prognosis. However, because of the ill-defined margins or dense adhesions to the neural tissue, subtotal removal has to be performed to avoid unacceptable postoperative complications. In the literature, 19 patients underwent surgery, and gross total resection was achieved in eight cases (42.1%), subtotal resection in 10 cases (52.6%), and biopsy sampling in one case (5.3%). The medulla was involved in our present cases, and the patients showed good results, although only subtotal removal was possible. Thus, based on the need to protect neurological functions, aggressive attempts to attain gross total removal were unnecessary.

Radiotherapy is considered beneficial for preventing tumor recurrence, particularly when total removal cannot be achieved. However, only five patients underwent postoperative radiotherapy, and two experienced tumor recurrence or metastasis. Regardless of the duration, rapid deterioration occurred in a few cases, most likely caused by venous thrombosis and tumor hemorrhage.

**Table 1**

- **Clinical features of primary SNs**
  - Ages: 22–78 years (mean 33.7 years)
  - Sex ratio: 2.3:1 (male/female)
  - Location:
    - Cervical: 6 (33.3%)
    - Thoracic: 12 (66.7%)
    - Lumbar: 2 (11.1%)
  - Symptoms:
    - Somatic pain: 18 (100%)
    - Numbness: 16 (88.9%)
    - Progressive weakness: 15 (83.3%)
    - Sudden weakness: 5 (27.8%)
    - Urinary retention: 1 (5.6%)
    - Bowel incontinence: 1 (5.6%)
  - Treatment:
    - Surgery: 19 (100%)
    - Postoperative radiotherapy: 4 (21.1%)
    - Palliative chemotherapy: 2 (10.5%)
  - Outcome:
    - Complete resection: 8 (42.1%)
    - Subtotal resection: 10 (52.6%)
    - Biopsy sampling: 1 (5.3%)
    - Recurrence: 2 (10.5%)
    - Metastasis: 1 (5.6%)

**Discussion**

Since Coca et al. described the first case in 1994, only 18 cases of primary SN have been reported in the English literature. Table 1 summarizes the clinical features of previous cases and our two patients. Of the 20 reported patients, 14 were male and 6 were female. Compared with CNs and other EVNs, in which gender predominance is not evident, the male/female ratio of primary SNs (2.3:1) suggests a strong male predilection. The mean age at presentation is 33.7 years, which is similar to that of other EVNs. The tumors tend to arise from the cervical and thoracic spinal regions. Two cases involved the medulla oblongata, and two tumors were located in the lumbar segment. In the previous cases, all the lesions were intramedullary, including one with an extramedullary component.

The signs and symptoms of SNs are consistent with those of other common intramedullary spinal tumors. The clinical presentations of SNs include somatic pain, numbness, progressive or sudden weakness in the limbs, and incomplete voiding when the conus medullaris is involved. The symptoms usually evolve over a period of months to years. Regardless of the duration, rapid deterioration occurred in a few cases, most likely caused by venous thrombosis and tumor hemorrhage.

The MRI features of primary SNs are variable and could be misleading, as shown in the previously reported cases. All the cases involved intramedullary tumors; associated syringomyelia could be found, but this finding was uncommon. The signals of primary SNs ranged from iso- to hypointensity on T₁-weighted images and iso- to hyperintensity on T₂-weighted images. The lesions could show homo- or heterogeneous enhancement after gadolinium administration and some had poorly defined tumor margins. These features were similar to those of spinal cord ependymomas and astrocytomas. In our two cases, variations in the preoperative MRI findings led to difficulties with the diagnosis. Both lesions involved the medulla. Thus, a definitive diagnosis of primary SN was difficult based on MRI alone, and a complete histopathological examination was required to differentiate between other common intramedullary tumors, such as ependymomas, astrocytomas, and oligodendrogliomas in particular.

The histogenesis of CN is poorly understood, but some theories have been proposed. CN may originate from cells that are committed to a neuronal phenotype or from bipotential progenitor cells in the periventricular matrix. The differential diagnosis for SN typically includes other intramedullary tumors, particularly ependymoma and oligodendroglioma. Neurocytomas have a fine neuropil-like fibrillary matrix instead of the coarser glial fibrillary matrix of ependymomas. Cells of ependymomas exhibit more angulated nuclei and are negative for Syn. Neurocytoma cells show clear perinuclear halos that resemble oligodendrogliomas. Thus, immunohistochemistry is often a necessary adjunct for the differential diagnosis.

Strong and diffuse immunostaining for Syn has been recognized as the most suitable and reliable diagnostic marker. The nuclear positivity for NeuN favors diagnosing SN over oligodendroglioma, although the latter can also occasionally express neuronal markers. In the literature, SNs have reportedly expressed some other neuronal markers, including NSE, neuron-associated class III beta-tubulin, and microtubule-associated protein 2. However, chromogranin and neurofilament proteins are generally absent.

Because of the benign nature and well differentiation of this tumor, complete resection is advised to ensure a relatively favorable prognosis. However, because of the ill-defined margins or dense adhesions to the neural tissue, subtotal removal has to be performed to avoid unacceptable postoperative complications. In the literature, 19 patients underwent surgery, and gross total resection was achieved in eight cases (42.1%), subtotal resection in 10 cases (52.6%), and biopsy sampling in one case (5.3%). The medulla was involved in our present cases, and the patients showed good results, although only subtotal removal was possible. Thus, based on the need to protect neurological functions, aggressive attempts to attain gross total removal were unnecessary.

Radiotherapy is considered beneficial for preventing tumor recurrence, particularly when total removal cannot be achieved. However, only five patients underwent postoperative radiotherapy, and two experienced tumor recurrence or metastasis. Regardless of the duration, rapid deterioration occurred in a few cases, most likely caused by venous thrombosis and tumor hemorrhage.
Primary Spinal Neurocytoma

Table 1 Summary of previously reported cases of primary spinal neurocytoma

<table>
<thead>
<tr>
<th>Author (Year)</th>
<th>Age (yrs)/gender</th>
<th>Tumor location</th>
<th>MRI findings</th>
<th>Treatment</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coca et al. (1994)</td>
<td>67/M</td>
<td>T11–T12 IM</td>
<td>NA</td>
<td>NA</td>
<td>GTR</td>
</tr>
<tr>
<td>Tatter et al. (1994)</td>
<td>65/M</td>
<td>C2–C6 IM</td>
<td>Homo iso</td>
<td>NA</td>
<td>Biopsy + RT</td>
</tr>
<tr>
<td>Stapleton et al. (1997)</td>
<td>12/M</td>
<td>C4–T1 IM</td>
<td>Iso</td>
<td>Iso</td>
<td>Heter</td>
</tr>
<tr>
<td>Stephan et al. (1999)</td>
<td>46/F</td>
<td>T12–L1 IM</td>
<td>Slight hypo</td>
<td>Slight hypo</td>
<td>Homo</td>
</tr>
<tr>
<td>Martin et al. (2002)</td>
<td>50/M</td>
<td>T2–T5 IM</td>
<td>Irregular iso</td>
<td>Irregular iso</td>
<td>Heter</td>
</tr>
<tr>
<td>Baehring et al. (2005)</td>
<td>13/M</td>
<td>T6–T10 IM</td>
<td>NA</td>
<td>NA</td>
<td>Heter</td>
</tr>
<tr>
<td>Sharma et al. (2005)</td>
<td>24/M</td>
<td>C5–T1 IM</td>
<td>Iso</td>
<td>Hyper</td>
<td>Homo</td>
</tr>
<tr>
<td>Singh et al. (2007)</td>
<td>8/M</td>
<td>T2–T8 IM</td>
<td>Hypo</td>
<td>Markedly hyper</td>
<td>Heter</td>
</tr>
<tr>
<td>Gokhan et al. (2008)</td>
<td>49/M</td>
<td>C3–C6 IM</td>
<td>NA</td>
<td>Homo iso</td>
<td>NA</td>
</tr>
<tr>
<td>Polli et al. (2009)</td>
<td>6/M</td>
<td>C1–C7 IM</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>15/M</td>
<td>C1–T11 IM</td>
<td>NA</td>
<td>NA</td>
<td>Heter</td>
</tr>
<tr>
<td></td>
<td>37/F</td>
<td>T12–L1 IM</td>
<td>NA</td>
<td>NA</td>
<td>Heter</td>
</tr>
<tr>
<td>Marucci et al. (2009)</td>
<td>51/M</td>
<td>T10–T11 IM</td>
<td>Hyper</td>
<td>NA</td>
<td>Homo</td>
</tr>
<tr>
<td>Tsai et al. (2011)</td>
<td>54/F</td>
<td>T3–T5 IM, EM</td>
<td>Iso</td>
<td>NA</td>
<td>Homo</td>
</tr>
<tr>
<td>Agarwal et al. (2011)</td>
<td>16/M</td>
<td>NA</td>
<td>Iso</td>
<td>Hyper</td>
<td>Homo</td>
</tr>
<tr>
<td></td>
<td>25/M</td>
<td>NA</td>
<td>Iso</td>
<td>Hyper</td>
<td>Homo</td>
</tr>
<tr>
<td>Gepp et al. (2012)</td>
<td>15/F</td>
<td>NA, IM</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Present cases</td>
<td>48/F</td>
<td>Medulla-T1 IM</td>
<td>Iso/hypo</td>
<td>Mixed hyper</td>
<td>Heter</td>
</tr>
<tr>
<td></td>
<td>26/M</td>
<td>Medulla-T4 IM</td>
<td>Iso/hypo</td>
<td>Hyper</td>
<td>Heter</td>
</tr>
</tbody>
</table>


recurrence in long-term follow-up evaluations. Compared to other cases in which only surgery was performed, the efficacy of adjuvant radiation therapy for controlling tumor recurrence was limited. It is difficult to comment on the role of chemotherapy because only one reported case used this therapy.

The postoperative course ranged from 3 months to 23 years. Good outcomes were obtained after surgery in 14 of 17 cases with follow-up evaluations. Tumor recurrence was rare, and only three recurrence cases were noted. Therefore, even when only subtotal resection was performed, most patients had a good prognosis because SNS usually grow slowly and have a low proliferation level. Because of the likelihood of long-term recurrence (more than 10 months), careful consecutive follow-up evaluations after initial treatment are essential.

Conflicts of Interest Disclosure

The authors have reported no conflicts of interest.

References


Neurol Med Chir (Tokyo) 54, May, 2014


Address reprint requests to: Yulun Xu, MD, PhD, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Chongwen District, Beijing 100050, China.

*E-mail: xuhuxi@sina.com*